• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Turns Lower; Getaround Shares Jump

    5/12/23 12:11:09 PM ET
    $DRMA
    $GETR
    $HRTX
    $IONM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Rental/Leasing Companies
    Consumer Discretionary
    Get the next $DRMA alert in real time by email

    U.S. stocks traded lower midway through trading, with the Dow Jones turning lower on Friday.

    The Dow traded down 0.25% to 33,226.13 while the NASDAQ fell 0.45% to 12,271.22. The S&P 500, also fell, dropping, 0.32% to 4,117.20.

    Check This Out: Top 5 Industrials Stocks That May Explode In Q2

     

    Leading and Lagging Sectors

    • Energy shares rose by 0.3% on Friday. Meanwhile, top gainers in the sector included Petróleo Brasileiro S.A. - Petrobras (NYSE:PBR), up 6%, and VOC Energy Trust (NYSE:VOC), up 4%.
    • In trading on Friday, consumer discretionary shares fell 0.9%.

     

    Top Headline

    US export prices increased by 0.2% from a month ago in April, while import prices rose 0.4% month-over-month in April.

     

    Equities Trading UP

    • ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) shares shot up 86% to $8.40 after the company reported the FDA's Advisory Committee voted in support of favorable benefit-risk assessment for neffy in the treatment of severe allergic reactions (Type 1), including anaphylaxis.
    • Shares of Dermata Therapeutics, Inc. (NASDAQ:DRMA) got a boost, shooting 49% to $2.8799 after the company highlighted recent corporate progress, and reported financial results for the first quarter.
    • Getaround, Inc. (NYSE:GETR) shares were also up, gaining 69% to $0.5590 after the company announced it is acquiring substantially all of the assets of HyreCar for an aggregate purchase price of $9.45 million.

     

    Equities Trading DOWN

    • TOP Financial Group Limited (NASDAQ:TOP) shares dropped 30% to $6.42 after the SEC said it is temporarily suspending trading in the securities of the company because of "recent, unusual, and unexplained market activity" raising concerns regarding the adequacy and accuracy of publicly-available information.
    • Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) were down 36% to $1.42 after the company reported mixed Q1 financial results.
    • Assure Holdings Corp. (NASDAQ:IONM) was down, falling 39% to $1.1828 after the company announced pricing of a $6 million underwritten public offering.

    Also Check This Out: Wall Street's Most Accurate Analysts Say Hold These 3 Materials Stocks Delivering High-Dividend Yields

     

    Commodities

    In commodity news, oil traded down 0.1% to $70.85 while gold traded down 0.3% at $2,015.30.

    Silver traded down 1.5% to $24.06 on Friday while copper rose 0.4% to $3.7250.

     

    Euro zone

    European shares were higher today. The eurozone’s STOXX 600 gained 0.37%, London’s FTSE 100 rose 0.27% while Spain’s IBEX 35 Index rose 0.56% The German DAX rose 0.46%, French CAC 40 rose 0.37% and Italy’s FTSE MIB Index rose 0.97%.

    Spain's annual consumer price inflation increased to 4.1% in April from 3.3% in the previous month, while annual inflation rate in France increased to 5.9% in April from 5.7% in the prior month.

    The UK economy grew 0.2% year-over-year during the first quarter, recording the smallest annual expansion since 2021. Industrial production in the UK rose 0.7% month-over-month in March, while trade deficit narrowed to £2.86 billion in March versus a revised £3.35 billion in the earlier month.

     

    Asia Pacific Markets

    Asian markets closed mixed on Friday, with Japan’s Nikkei 225 gaining 0.90%, Hong Kong’s Hang Seng Index dropping 0.59% and China’s Shanghai Composite Index falling 1.12%. India’s S&P BSE Sensex rose 0.3%.

    Hong Kong’s economy expanded 2.7% year-over-year in the first quarter versus a revised 4.1% contraction in the earlier quarter. Annual inflation rate in India eased to 4.7% in April from 5.7% in March.

     

    Economics

    • U.S. export prices increased by 0.2% from a month ago in April, while import prices rose 0.4% month-over-month in April.
    • The University of Michigan consumer sentiment dropped to a six-month low level of 57.7 in May from 63.5 in the prior month.

    Now Read This: Over $5M Bet On This Communication Services Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

     

    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 106,790,390 cases with around 1,162,690 deaths. India confirmed a total of at least 44,978,170 cases and 531,750 deaths, while France reported over 40,029,700 COVID-19 cases with 166,860 deaths. In total, there were at least 688,143,330 cases of COVID-19 worldwide with more than 6,873,530 deaths.

    Get the next $DRMA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DRMA
    $GETR
    $HRTX
    $IONM

    CompanyDatePrice TargetRatingAnalyst
    ARS Pharmaceuticals Inc.
    $SPRY
    11/4/2025$30.00Buy
    Roth Capital
    ARS Pharmaceuticals Inc.
    $SPRY
    9/4/2025$40.00Buy
    Roth Capital
    Heron Therapeutics Inc.
    $HRTX
    6/9/2025$6.00Buy
    H.C. Wainwright
    Petroleo Brasileiro S.A. Petrobras
    $PBR
    6/9/2025Buy → Neutral
    BofA Securities
    Petroleo Brasileiro S.A. Petrobras
    $PBR
    5/15/2025$15.30Hold → Buy
    Jefferies
    ARS Pharmaceuticals Inc.
    $SPRY
    3/7/2025$30.00Sector Outperform
    Scotiabank
    Petroleo Brasileiro S.A. Petrobras
    $PBR
    3/5/2025$15.00Hold → Buy
    HSBC Securities
    ARS Pharmaceuticals Inc.
    $SPRY
    2/10/2025$40.00Outperform
    Oppenheimer
    More analyst ratings

    $DRMA
    $GETR
    $HRTX
    $IONM
    SEC Filings

    View All

    SEC Form 6-K filed by Petroleo Brasileiro S.A. Petrobras

    6-K - PETROBRAS - PETROLEO BRASILEIRO SA (0001119639) (Filer)

    2/6/26 7:03:59 AM ET
    $PBR
    Oil & Gas Production
    Energy

    SEC Form 6-K filed by Petroleo Brasileiro S.A. Petrobras

    6-K - PETROBRAS - PETROLEO BRASILEIRO SA (0001119639) (Filer)

    2/6/26 6:02:03 AM ET
    $PBR
    Oil & Gas Production
    Energy

    SEC Form 6-K filed by Petroleo Brasileiro S.A. Petrobras

    6-K - PETROBRAS - PETROLEO BRASILEIRO SA (0001119639) (Filer)

    2/4/26 4:27:17 PM ET
    $PBR
    Oil & Gas Production
    Energy

    $DRMA
    $GETR
    $HRTX
    $IONM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Rubric Capital Management Lp bought $3,580,838 worth of shares (2,387,225 units at $1.50) (SEC Form 4)

    4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

    8/12/25 6:00:17 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Morgan Adam bought $2,649,819 worth of shares (1,766,546 units at $1.50) (SEC Form 4)

    4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

    8/12/25 5:02:36 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ra Capital Management, L.P. bought $13,289,410 worth of shares (1,401,299 units at $9.48) (SEC Form 4)

    4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

    3/27/24 7:37:52 PM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRMA
    $GETR
    $HRTX
    $IONM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZYNRELEF KIT issued to HERON THERAPS INC

    Submission status for HERON THERAPS INC's drug ZYNRELEF KIT (SUPPL-18) with active ingredient BUPIVACAINE; MELOXICAM has changed to 'Approval' on 11/21/2024. Application Category: NDA, Application Number: 211988, Application Classification: Labeling

    11/22/24 4:36:11 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for APONVIE issued to HERON THERAPS INC

    Submission status for HERON THERAPS INC's drug APONVIE (SUPPL-3) with active ingredient APREPITANT has changed to 'Approval' on 03/05/2024. Application Category: NDA, Application Number: 216457, Application Classification: Labeling

    3/11/24 4:38:31 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for CINVANTI issued to HERON THERAPS INC

    Submission status for HERON THERAPS INC's drug CINVANTI (SUPPL-15) with active ingredient APREPITANT has changed to 'Approval' on 03/05/2024. Application Category: NDA, Application Number: 209296, Application Classification: Labeling

    3/11/24 4:38:29 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRMA
    $GETR
    $HRTX
    $IONM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NAMIBIAN INDUSTRY RELATED CATALYSTS SUPPORT STRATEGIC HOLDING OF ASSETS IN MULTIPLE BASINS

    VANCOUVER, BC, Feb. 9, 2026 /CNW/ - Stamper Oil & Gas Corp. (the "Company" or "Stamper") (TSXV:STMP) (OTC:STMGF) (Germany: TMP0) highlights recent new entrant activity on Petroleum Exploration Licence ("PEL") 104 offshore Namibia in the Lüderitz Basin sit adjacent to Stamper's PEL 107 and PEL 104 assets supporting the Company's strategy of holding four PELs in three of Namibia's four offshore Basins. Grayson M. Andersen, Chief Executive Officer of Stamper commented: "With TotalEnergies and Petrobras entering the Lüderitz Basin offshore Namibia, it confirms our strategy of acquiring high quality oil and gas exploration assets offshore Namibia, in proximity to PELs operated by supermajors. Our

    2/9/26 6:00:00 AM ET
    $PBR
    $TTE
    Oil & Gas Production
    Energy

    EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg

    EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma's partner, ALK-Abelló A/S, who owns the rights to market EURneffy in the EU, will distribute following expected authorization by the European Commission SAN DIEGO, Feb. 02, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recomme

    2/2/26 8:00:00 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use

    California joins 23 other states eligible to receive free neffy® (epinephrine nasal spray) at schools SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, announced today that California, the state where ARS Pharma is headquartered, is now eligible for its neffyinSchools program. Type 1 allergic reactions, including anaphylaxis, can happen quickly and be caused by foods, insects, medication, exercise, or other unknown causes and can only be treated with epinephrine. It is estimated tha

    1/21/26 8:00:00 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRMA
    $GETR
    $HRTX
    $IONM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $DRMA
    $GETR
    $HRTX
    $IONM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Director Cusack Thomas was granted 53,960 shares (SEC Form 4)

    4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

    2/3/26 10:00:07 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP, Chief Financial Officer Duarte Ira

    4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

    2/3/26 10:00:10 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Johnson Craig A was granted 53,960 shares (SEC Form 4)

    4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

    2/3/26 10:00:08 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital resumed coverage on ARS Pharmaceuticals with a new price target

    Roth Capital resumed coverage of ARS Pharmaceuticals with a rating of Buy and set a new price target of $30.00

    11/4/25 8:07:28 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on ARS Pharmaceuticals with a new price target

    Roth Capital initiated coverage of ARS Pharmaceuticals with a rating of Buy and set a new price target of $40.00

    9/4/25 7:57:34 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Heron Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Heron Therapeutics with a rating of Buy and set a new price target of $6.00

    6/9/25 7:51:39 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRMA
    $GETR
    $HRTX
    $IONM
    Leadership Updates

    Live Leadership Updates

    View All

    Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors

    CARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the appointment of Thomas Cusack to its Board of Directors. Mr. Cusack has extensive experience in matters related to corporate finance, investment management, and corporate governance. Mr. Cusack was appointed to the Board pursuant to the Cooperation Agreement entered into between the Company and Rubric Capital Management LP, dated as of August 8, 2025. Mr. Cusack was appointed as a director of Heron as of October 27, 2025.  Mr. Cusack has more than 20 years of experience in investment management and corporate finance. 

    10/29/25 5:58:14 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ADARx Pharmaceuticals Appoints Industry Veteran, Laura Shawver, Ph.D., as Board Chair

    – Accomplished biopharma executive and entrepreneur brings a 25-year track record of upscaling valuable companies and realizing the potential of their innovations – SAN DIEGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, today announced the appointment of Laura Shawver, Ph.D., as Chair of its Board of Directors. "We are honored to welcome Dr. Shawver to our Board. Laura's outstanding track record of driving strategic growth and developing innovative therapies comes at a pivotal time as we scale to advance our pipeline and expand the impact of our next-generation

    9/17/25 9:00:00 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer

    CARY, N.C., April 28, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the appointment of Mark Hensley as Chief Operating Officer. Mr. Hensley has more than fifteen years of experience in a variety of sales and operations positions within the pharmaceutical industry. "I am excited to welcome Mark to Heron as our new Chief Operating Officer," said Craig Collard, Chief Executive Officer of Heron. "Mark brings extensive operational and leadership experience that positions him to play a pivotal role in our next phase of growth. His experience will be instrumental in ensuring we operate with efficienc

    4/28/25 6:55:00 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRMA
    $GETR
    $HRTX
    $IONM
    Financials

    Live finance-specific insights

    View All

    ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)

    $32.5 million in revenue, including $31.3 million in neffy U.S. net product revenue in third quarter of 2025 Continued U.S. product growth driven by direct-to-consumer (DTC) investments and real-world evidence, expected to accelerate with seamless prescribing experience Strong balance sheet of $288.2 million cash, cash equivalents and short-term investments anticipated to fund operations through cash-flow break-even Conference call to be held today, November 10, 2025, at 5:30 a.m. PT / 8:30 a.m. ET  SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better pro

    11/10/25 6:00:00 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress

    Generated Q3 2025 Net Revenue of $38.2 million and year-to-date revenue of $114.3 million; reaffirmed 2025 Net Revenue Guidance of $153 million - $163 million and adjusted EBITDA of $9.0 - $13.0 millionZYNRELEF® Net Revenue grew 49% in Q3 2025, as compared to Q3 2024, continuing momentum with the launch of the Vial Access Needle (VAN) and enhanced incentive program with key distributorsAPONVIE® Net Revenue grew 173% in Q3 2025, as compared to Q3 2024, supported by increased adoption and momentum building with the newly launched dedicated sales team in Q3 2025 CARY, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage

    11/4/25 8:00:00 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results

    SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Monday, November 10, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its third quarter 2025 financial results and business highlights. Dial-in information for conference participants may be obtained by registering for the event. To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company's website.

    11/3/25 8:00:00 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRMA
    $GETR
    $HRTX
    $IONM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Dermata Therapeutics Inc.

    SC 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    11/14/24 5:07:13 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Getaround Inc.

    SC 13D/A - Getaround, Inc (0001839608) (Subject)

    11/14/24 5:06:28 PM ET
    $GETR
    Rental/Leasing Companies
    Consumer Discretionary

    SEC Form SC 13G filed by Heron Therapeutics Inc.

    SC 13G - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Subject)

    11/12/24 9:32:11 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care